您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > N-acetyl-2-carboxy Benzenesulfonamide
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
N-acetyl-2-carboxy Benzenesulfonamide
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
N-acetyl-2-carboxy Benzenesulfonamide图片
CAS NO:849067-18-1
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品介绍
Cas No.849067-18-1
化学名2-[(acetylamino)sulfonyl]-benzoic acid
Canonical SMILESCC(=O)NS(=O)(=O)c1ccccc1C(=O)O
分子式C9H9NO5S
分子量243.2
溶解度≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 0.06 and 0.25 μM for COX-1 and COX-2, respectively

N-acetyl-2-carboxy Benzenesulfonamide is a non-selective inhibitor of COX.

Pharmaceutical inhibition of COX is able to provide relief from the symptoms of inflammation and pain. Nonsteroidal anti-inflammatory drugs, such as aspirin, exert its effect via inhibition of COX.

In vitro: Previous in-vitro COX-1/COX-2 inhibition studies showed that N-acetyl-2-carboxy benzenesulfonamide was a more potent inhibitor than aspirin, and like aspirin. Moreover, N-acetyl-2-carboxy benzenesulfonamide was found to be a nonselective COX-2 inhibitor. In addition, the molecular modeling (docking) study demonstrated that the SO2NHCOCH3 substituent present in N-acetyl-2-carboxy benzenesulfonamide, like the acetoxy substituent in aspirin, was suitably positioned to acetylate the Ser530 hydroxyl group in the COX-2 primary binding site [1].

In vivo: Animal study showed that N-acetyl-2-carboxy benzenesulfonamide and its C-4 2,4-difluorophenyl derivative had superior antiinflammatory activity (oral dosing) in a carrageenan-induced rat paw edema assay compared to aspirin. In addition, N-acetyl-2-carboxy benzenesulfonamide and its C-4 2,4-difluorophenyl derivative exhibited comparable analgesic activity to iflunisal, and superior analgesic activity compared to aspirin [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Chen, Q. H.,Rao, P.N.P., and Knaus, E.E. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: A novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & Medicinal Chemistry 13, 2459-2468 (2005).